University of Arkansas

Bioventures, LLC

Samuel Michael Owens

Frank Ivy Carroll

Philip Abraham

Ralph L Henry

Alicia Brown

Ralph Henry

The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.

Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof

The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.

Anti-(+)&#x2014;methamphetamine monoclonal antibodies

The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.

Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs

The invention includes synthetic immunochemical haptens for the generation of antibodies, the antibodies, and the medical treatment applications for using the antibodies. The antibodies are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants, and will have insignificant cross-reactivity with endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses or fetus from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.

Growing community of inventors

Little Rock, AR, United States of America

Samuel Michael Owens